Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luspatercept for Refractory Poor Platelet Engraftment after Allogeneic HSCT
ChiCTR2500111793Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Nov 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of luspatercept in Delayed platelet engraftment (DPE) and iron overload, sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Response rate at 3 weeks. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
luspatercept
03
Conditions
Delayed platelet engraftment (DPE)iron overload
Beyond the preview
Go deeper on ChiCTR2500111793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111793.